CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
• By The Pink Sheet Daily
FDA's Center for Drug Evaluation and Research says its discussions with Genentech about a proposed confirmatory trial in metastatic breast cancer are irrelevant to the withdrawal of bevacizumab's accelerated approval for the indication.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights